ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

0H22 Bioinvent International Ab

18.10
0.00 (0.00%)
17 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioinvent International Ab LSE:0H22 London Ordinary Share SE0015244520 BIOINVENT INTERNATIONAL ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 18.10 17.20 19.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Change in the number of shares and votes in BioInvent International AB

31/03/2021 7:48am

PR Newswire (US)


Bioinvent International Ab (LSE:0H22)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Bioinvent International Ab Charts.

LUND, Sweden, March 31, 2021 /PRNewswire/ -- BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per March 31, 2021 amounts to 58,471,096 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of MSEK 819 to international and Swedish institutional investors by issuance of 16,260,601 shares, announced on February 23, 2021 and approved by the General Meeting on March 23, 2021.

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:

Cecilia Hofvander

Senior Director Investor Relations

+46 (0)46 286 85 50

cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)

Co. Reg. No.: 556537-7263

Visiting address: Ideongatan 1

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

www.bioinvent.com

This information is information that BioInvent International AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:30 a.m. CEST on March 31, 2021.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioinvent-international-ab/r/change-in-the-number-of-shares-and-votes-in-bioinvent-international-ab,c3317329

The following files are available for download:

https://mb.cision.com/Main/583/3317329/1395175.pdf

Change in the number of shares and votes in BioInvent International AB

Cision View original content:http://www.prnewswire.com/news-releases/change-in-the-number-of-shares-and-votes-in-bioinvent-international-ab-301259271.html

SOURCE BioInvent International AB

Copyright 2021 PR Newswire

1 Year Bioinvent International Ab Chart

1 Year Bioinvent International Ab Chart

1 Month Bioinvent International Ab Chart

1 Month Bioinvent International Ab Chart

Your Recent History

Delayed Upgrade Clock